arrow
T

Tai-Chung Tseng

hepatitis research center national taiwan university hospital
H指数:41
被引数:6,259

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Risk Factors for Advanced Fibrosis in Pathology‐Proven Steatotic Liver Disease: Emphasis on Nonelder Subjects

病理学证实的脂肪性肝病中晚期肝纤维化的临床危险因素:侧重于非老年受试者

2026-10-200
PRE
Serum Golgi Protein 73 as a Noninvasive Marker of Hepatic Fibrosis in Chronic Hepatitis C Virus Infection

血清高尔基体蛋白73作为慢性丙型肝炎病毒感染中肝纤维化的无创性标志物

2026-10-190
PRE
Early post-transplant molecular residual disease predicts outcomes in myelodysplastic neoplasms/syndromes and acute myeloid leukemia undergoing allogeneic transplantation

移植早期分子残留病灶可预测接受异基因移植的骨髓增生异常肿瘤/综合征和急性髓系白血病的结局

2026-10-010
OAAI
HBV RNA, HBcrAg, and HBsAg levels at year 6 do not predict HCC risk in patients with cirrhosis on long-term entecavir therapy

HBV RNA、HBcrAg和HBsAg水平在6年时不预测长期恩替卡韦治疗患者的肝硬化患者发生HCC的风险

2026-08-080
PRE
Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

血清Mac-2结合蛋白糖化异构体对代谢功能障碍相关脂肪性肝病合并丙型肝炎病毒感染患者肝纤维化的预测价值

2025-11-010
PRE
Non-negligible risk of HBV reactivation among rheumatoid arthritis patients receiving JAK inhibitors: bridging the evidence gap

类风湿关节炎患者使用JAK抑制剂后存在不可忽视的HBV再激活风险:弥合证据差距

2025-08-010
PRE
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus Infection

直接作用抗病毒药物诱导的丙型肝炎病毒感染治愈患者发生2型糖尿病和糖尿病前期的风险

2025-02-212
PRE
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis C

Hong, C.-M.; Su, T.-H.; Hsu, S.-J.; Tseng, T.-C.; Liu, C.-H.; Yang, H.-C.; Kao, J.-H.; Chen, P.-J.; Cheng, P.-N.; Hung, C.-H.; 等. 将中性粒细胞与淋巴细胞比值加入Pre-DAA FIB-4不会增加对丙型肝炎患者新发肝并发症的预测价值。中华医事杂志. 2024; 已录用. [Google Scholar] [CrossRef] [PubMed]

2024-11-020
OAAI
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals
2024-05-151
OA
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals
2024-04-131
PRE